Australia markets closed

Replimune Group Inc (7R8.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
18.50-0.90 (-4.64%)
As of 08:04AM CET. Market open.
Full screen
Previous close19.40
Open18.50
Bid18.80 x 0
Ask19.40 x 0
Day's range18.50 - 18.50
52-week range12.30 - 25.80
Volume0
Avg. volume2
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date01 Feb 2023 - 06 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

    WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET. About Replimune Replimune Group, Inc., headqu

  • GlobeNewswire

    Replimune to Host Virtual Investor Event on December 7, 2022

    Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with

  • GlobeNewswire

    Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

    Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end An update on the RP2/3 development program remains on track to be provided by year end Completed $200 million term-loan tha